Catalysts / BIOA
Upcoming FDA decisions and readouts we track for BioAge Labs, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for BioAge Labs (BIOA, listed on Nasdaq). It concerns BGE-102 (Diabetic macular oedema (oral NLRP3 inhibitor)).
First on the list: the Phase 2 readout for BGE-102 (Diabetic macular oedema (oral NLRP3 inhibitor)), guided by the company to H2 2027.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 07 Oct 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| BioAge Labs BIOA · Nasdaq | BGE-102 | Diabetic macular oedema (oral NLRP3 inhibitor) | H2 2027 company guidance |
Phase 2 readout | Verified | 8-K ↗ | Yes |
FreeBioList